Market Cap 3.60B
Revenue (ttm) 233.18M
Net Income (ttm) -321.55M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -137.90%
Debt to Equity Ratio 0.00
Volume 1,807,200
Avg Vol 1,898,438
Day's Range N/A - N/A
Shares Out 89.47M
Stochastic %K 71%
Beta 0.89
Analysts Strong Sell
Price Target $41.64

Company Profile

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport di...

Industry: Biotechnology
Sector: Healthcare
Phone: 888 969 7879
Address:
3611 Valley Centre Drive, Suite 300, San Diego, United States
merlin8121
merlin8121 Dec. 26 at 8:20 PM
$TVTX https://www.merlintrader.com/tvtx-travere-therapeutics-2/
0 · Reply
111ggg
111ggg Dec. 26 at 4:12 PM
$TVTX Should fall back to 37-38 range where I will rebuy shares I sold on Wed. Should see 45-47 some time next year.
0 · Reply
OptionRunners
OptionRunners Dec. 26 at 4:03 PM
$TVTX this morning. Check the OI change for confirmation. IV up big in them
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 25 at 3:34 PM
Actionable Trade Alert for $TVTX: Market Context: $TVTX is currently trading at $40.28, nearing its 60-day high of $42.13, indicating a bullish sentiment. The RSI at 67.69 suggests that the stock is approaching overbought territory, which could lead to a pullback. However, the strong upward trend is supported by the moving averages. Directional Bias: The stock is above both the 30-day MA (35.25) and the 50-day MA (33.43), reinforcing a bullish outlook. The recent high-low range shows significant volatility, with a 60D low of $23.22, providing a solid base for potential gains. Trade Plan: - Suggested Entry: $40.50 (slightly above the last close to confirm momentum) - Stop Loss: $38.00 (below recent support levels) - Take Profit Targets: 1. $42.00 (4.3% gain) 2. $44.00 (8.8% gain) 3. $47.00 (16.6% gain, 17% ROI+) This plan capitalizes on the bullish trend while managing risk effectively. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
EchoAnalysis
EchoAnalysis Dec. 25 at 2:20 AM
$TVTX has been on IBD top 15 list for several weeks; up +17% today and up +170% in last 6 months.
0 · Reply
OpenOutcrier
OpenOutcrier Dec. 24 at 6:00 PM
RECAP 12/24 +Pos Comments: $TVTX + Cantor RECAP 12/24 -Neg Comments: $LODE - Noble Capital $CANF - D Boral Capital Live Breaking trading news www.openoutcrier.com
0 · Reply
notreload_ai
notreload_ai Dec. 24 at 5:16 PM
FDA confirms proteinuria reduction as valid FSGS approval endpoint in Dimerix feedback, boosting confidence in $TVTX upcoming Filspari decision. https://notreload.xyz/fda-backs-proteinuria-endpoint-boost-for-travere-stock/
0 · Reply
Meigs1865
Meigs1865 Dec. 24 at 5:14 PM
$TVTX Travere Therapeutics (NASDAQ: TVTX) stock surged over 15% today, reaching a new 52-week high of $40.38, amid positive analyst commentary linking the move to a recent FDA update from competitor Dimerix Limited. Dimerix announced on December 24, 2025, that the FDA provided written feedback reconfirming the percentage reduction in proteinuria at two years as an appropriate primary endpoint for full approval in their Phase 3 ACTION3 trial for DMX-200 in focal segmental glomerulosclerosis (FSGS).
0 · Reply
cfromhertz
cfromhertz Dec. 24 at 4:55 PM
$TVTX *TRAVERE SEEN POSITIVELY AT CANTOR AFTER DIMERIX UPDATE ON FSGS
0 · Reply
Hdhhiej
Hdhhiej Dec. 24 at 4:50 PM
$TVTX $FEIM $C Get new opportunities in the new year
0 · Reply
Latest News on TVTX
3 Potential Mid-Cap Biotech Buyout Targets In 2026

Dec 3, 2025, 6:22 PM EST - 24 days ago

3 Potential Mid-Cap Biotech Buyout Targets In 2026

COGT IBB XBI CYTK


Travere Therapeutics, Inc. (TVTX) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 11:26 PM EDT - 2 months ago

Travere Therapeutics, Inc. (TVTX) Q3 2025 Earnings Call Transcript


3 Potential Biotech Acquisition Targets

Sep 19, 2025, 12:53 PM EDT - 3 months ago

3 Potential Biotech Acquisition Targets

AZN ETNB INCY MLYS SNDX


Travere Therapeutics: Compelling FILSPARI Growth Is Hard To Ignore

Aug 12, 2025, 12:15 PM EDT - 4 months ago

Travere Therapeutics: Compelling FILSPARI Growth Is Hard To Ignore


merlin8121
merlin8121 Dec. 26 at 8:20 PM
$TVTX https://www.merlintrader.com/tvtx-travere-therapeutics-2/
0 · Reply
111ggg
111ggg Dec. 26 at 4:12 PM
$TVTX Should fall back to 37-38 range where I will rebuy shares I sold on Wed. Should see 45-47 some time next year.
0 · Reply
OptionRunners
OptionRunners Dec. 26 at 4:03 PM
$TVTX this morning. Check the OI change for confirmation. IV up big in them
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 25 at 3:34 PM
Actionable Trade Alert for $TVTX: Market Context: $TVTX is currently trading at $40.28, nearing its 60-day high of $42.13, indicating a bullish sentiment. The RSI at 67.69 suggests that the stock is approaching overbought territory, which could lead to a pullback. However, the strong upward trend is supported by the moving averages. Directional Bias: The stock is above both the 30-day MA (35.25) and the 50-day MA (33.43), reinforcing a bullish outlook. The recent high-low range shows significant volatility, with a 60D low of $23.22, providing a solid base for potential gains. Trade Plan: - Suggested Entry: $40.50 (slightly above the last close to confirm momentum) - Stop Loss: $38.00 (below recent support levels) - Take Profit Targets: 1. $42.00 (4.3% gain) 2. $44.00 (8.8% gain) 3. $47.00 (16.6% gain, 17% ROI+) This plan capitalizes on the bullish trend while managing risk effectively. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
EchoAnalysis
EchoAnalysis Dec. 25 at 2:20 AM
$TVTX has been on IBD top 15 list for several weeks; up +17% today and up +170% in last 6 months.
0 · Reply
OpenOutcrier
OpenOutcrier Dec. 24 at 6:00 PM
RECAP 12/24 +Pos Comments: $TVTX + Cantor RECAP 12/24 -Neg Comments: $LODE - Noble Capital $CANF - D Boral Capital Live Breaking trading news www.openoutcrier.com
0 · Reply
notreload_ai
notreload_ai Dec. 24 at 5:16 PM
FDA confirms proteinuria reduction as valid FSGS approval endpoint in Dimerix feedback, boosting confidence in $TVTX upcoming Filspari decision. https://notreload.xyz/fda-backs-proteinuria-endpoint-boost-for-travere-stock/
0 · Reply
Meigs1865
Meigs1865 Dec. 24 at 5:14 PM
$TVTX Travere Therapeutics (NASDAQ: TVTX) stock surged over 15% today, reaching a new 52-week high of $40.38, amid positive analyst commentary linking the move to a recent FDA update from competitor Dimerix Limited. Dimerix announced on December 24, 2025, that the FDA provided written feedback reconfirming the percentage reduction in proteinuria at two years as an appropriate primary endpoint for full approval in their Phase 3 ACTION3 trial for DMX-200 in focal segmental glomerulosclerosis (FSGS).
0 · Reply
cfromhertz
cfromhertz Dec. 24 at 4:55 PM
$TVTX *TRAVERE SEEN POSITIVELY AT CANTOR AFTER DIMERIX UPDATE ON FSGS
0 · Reply
Hdhhiej
Hdhhiej Dec. 24 at 4:50 PM
$TVTX $FEIM $C Get new opportunities in the new year
0 · Reply
aaxaa
aaxaa Dec. 24 at 4:36 PM
0 · Reply
MaverikIT
MaverikIT Dec. 24 at 4:25 PM
@Jblack500 @WAJeff @cynicaloptimist @FannyPackin @Thelonius_Stonk @osubuckeye @Clargy $AGIO $TVTX $FEIM $KOD
0 · Reply
Chartist0_0
Chartist0_0 Dec. 24 at 4:24 PM
$TVTX $TGTX Is TVTX a bargain by comparison?
1 · Reply
RonIsWrong
RonIsWrong Dec. 24 at 4:15 PM
$TVTX wow, huge breakout here. any news? (and congrats to the longs on a great year here) (no position)
3 · Reply
TheGunnerAB
TheGunnerAB Dec. 24 at 3:16 PM
$TGTX Amazing what a one character typo $TVTX can cost you! 😆🤣
2 · Reply
ap20
ap20 Dec. 24 at 2:52 PM
$TVTX Wow..
1 · Reply
InterdependentI
InterdependentI Dec. 24 at 12:13 PM
$TVTX Future price discovery depends on how external catalysts materialize before balance-sheet pressure intensifies. Failure to demonstrate progress would likely keep valuation capped.
0 · Reply
aaxaa
aaxaa Dec. 22 at 7:30 PM
0 · Reply
LeeBeckwith675
LeeBeckwith675 Dec. 22 at 6:20 PM
$TVTX trades in biotech. AMBR announced continued progress toward full VARA authorization following in-principle approval. https://www.prnewswire.com/apac/news-releases/amber-premium-fze-secures-in-principle-approval-from-vara-for-virtual-asset-service-provider-license-in-dubai-302644821.html
0 · Reply
Doozio
Doozio Dec. 21 at 4:36 PM
$VTYX all the way up da Roger while $TVTX is nice n tight with huckleberries @ da $$$. It was always ENTA 🐒🍌🧠⏰♾️
0 · Reply
Smellmahass
Smellmahass Dec. 21 at 3:36 PM
$TVTX If approved it will be approved early like CYTK.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 5:30 PM
Actionable Trade Alert for $TVTX: Market Context: $TVTX is currently trading at $34.49, showing a neutral RSI of 44.7, indicating no immediate overbought or oversold conditions. The stock is near its 30-day moving average (MA30) of $34.9, suggesting potential resistance. The 60-day high of $37.5 presents a target for upward movement, while the low of $22.06 indicates a solid support level. Directional Bias: The stock's price is above the 50-day moving average (MA50) of $32.57, indicating a bullish bias. The ATR of 1.52 suggests moderate volatility, allowing for potential price swings. Trade Plan: - Suggested Entry: $34.50 - Stop Loss: $32.50 (approximately 5.8% risk) - Take Profit Targets: 1. $36.00 (4.3% gain) 2. $37.00 (7.6% gain) 3. $40.50 (17.5% gain) This plan aims for a minimum 17% ROI on the third target while managing risk effectively. https://privateprofiteers.com
1 · Reply